Evidence mapPaperPMID 34531310Full record

ArticleDiabetes care2021

Development and Progression of Diabetic Retinopathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study.

TODAY Study Group

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Retinal Neurophysiological Parameters in Young Patients With Type 1 Diabetes.Investigative ophthalmology & visual science · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 3 countries.

TODAY Study Group
Kimberly-Clark (Canada) · CA

Funding

Statistics Center for Pediatric Type 2 Diabetes TherapyU01DK061230 · GEORGE WASHINGTON UNIVERSITY · 2001 to 2005
$69.5M
Management of Pediatric Type 2 Diabetes MellitusU01DK061239 · CHILDRENS HOSPITAL OF PHILADELPHIA · 2001 to 2005
$4.6M
Multi-Center Study of the Treatment of T2DM in YouthU01DK061212 · YALE UNIVERSITY · 2001 to 2005
$3.9M
Type 2 Diabetes in Youth: Beta Cell PreservationU01DK061254 · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · 2001 to 2005
$3.6M
Treatment Alternatives in Pediatric Type 2 DiabetesU01DK061242 · UNIVERSITY OF COLORADO DENVER · 2001 to 2005
$3.5M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · UNIVERSITY OF COLORADO DENVER · 2025 to 2025
$1.3M
The Next Generation of Innovative Cardiovascular Clinical/Translational ResearchersK24HL145076 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KRISTEN Jane NADEAU · 2022 to 2023
$230k
NHLBI NIH HHS K24 HL145076NIDDK NIH HHS P30 DK116073NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254
6 · The paper itself

Abstract

objectiveThe Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study reported a 13.9% prevalence of diabetic retinopathy (DR) in youth with mean ± SD type 2 diabetes duration of 4.9 ± 1.5 years. After 7 years of additional follow-up, we report the risk factors for progression of DR in the TODAY cohort. RESEARCH DESIGN AND

methodsRetinal photographs (

resultsWith mean ± SD age of 25.4 ± 2.5 years and diabetes duration of 12.0 ± 1.5 years, there was a 49% prevalence of any DR among participants. Prevalence by DR stage was as follows: 39% for very mild or mild nonproliferative DR (NPDR), 6% moderate to severe NPDR, and 3.8% proliferative DR. Compared with nonprogressors, participants who progressed three or more steps had significantly lower BMI, higher HbA

conclusionsPoor glycemic control of youth-onset type 2 diabetes imparts a high risk for progression of DR, including advanced, sight-threatening disease by young adulthood.

Identifiers

PMID34531310
PMCPMC9174974
OpenAlexW4251173987

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.